IN
Indaptus Therapeutics, Inc.
INDP · NASDAQ
$3.77 -4.07% (-$0.16)
1M +243.97%
Market Cap $349.9M
P/E Ratio -
Div. Yield -
ROE 302.75%
Bulios Fair Price
$2.5
33.7% downside
Current Price
$3.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INDP is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 30.77x
PEG N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 49.61%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 302.75%
ROA 128.66%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 19.48x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
25 /100
Unstable EPS volatility 717.96%
Profitable years 0
Beta 1.17x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INDP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Junyi Dai
Employees
5
Headquarters
New York City
Upcoming events
17 NOV
Earnings
Upcoming earnings report